MediLink reported interim Phase 3 results for tambotatug pelitecan (Tam-Peli; YL-201), a B7-H3-targeted antibody-drug conjugate with a dual release payload, beating topotecan on overall survival in Chinese patients with relapsed small-cell lung cancer. The trial reduced the risk of death by 54% (median OS 13.3 vs. 9.4 months; HR 0.46; p<0.0001) and also delivered higher response rates (59.1% vs. 9.7%). Results were shared at the IASLC 2026 World Conference on Lung Cancer as a late-breaking abstract, with publication planned alongside the conference. The program also extends progression-free survival (median PFS 7.4 vs. 2.8 months), while the New Drug Application filing in China was accepted for review by CDE. Roche is developing and commercializing Tam-Peli outside mainland China, Hong Kong, and Macau, and said it plans to accelerate global trial initiation across tumor types. The survival signal strengthens the case for B7-H3 ADCs as a potential post-platinum backbone in SCLC.